AMNEAL PHARMACEUTICALS, INC.
AMRX Healthcare Drug Manufacturers Specialty & Generic
AMNEAL PHARMACEUTICALS, INC.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 billion, up 8.05% from fiscal 2024. In the quarter to June 2026, revenue grew 9.89%, EPS grew 157.1%, free cash flow fell 351.4% and total debt rose 8.22%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow AMRX
AMNEAL PHARMACEUTICALS, INC. (AMRX) EV/Sales
As of 16 October 2026, AMNEAL PHARMACEUTICALS, INC. (AMRX) trades at a EV/Sales of 2.8×. Over the past ten years it has ranged from 1.2× (April 2023) to 4.5× (August 2018); the current reading is higher than 93% of that period. That is in line with the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.1× | 17.97% |
| FY2024 | 1.7× | 16.10% |
| FY2023 | 1.5× | 10.56% |
| FY2022 | 1.4× | (11.27%) |
| FY2021 | 1.5× | (4.76%) |
| FY2020 | 1.6× | (17.69%) |
| FY2019 | 2.0× | (22.57%) |
| FY2018 | 2.5× | 61.17% |
| FY2017 | 1.6× | 0.00% |
| FY2016 | 1.6× | 0.00% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.6× | 23.94% |
| Mar 2026 | 2.1× | 1.41% |
| Dec 2025 | 2.1× | 10.11% |
| Sep 2025 | 1.9× | 8.22% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| RGC Regencell Bioscience Holdings Limited compare | n/m |
| HIMS Hims & Hers Health, Inc. compare | 2.7× |
| AMRX AMNEAL PHARMACEUTICALS, INC. | 2.8× |
| RDY Dr. Reddy's Laboratories Ltd compare | 2.9× |
| INDV Indivior Pharmaceuticals Inc. compare | 3.1× |
| LNTH Lantheus Holdings, Inc. compare | 4.2× |
| ALKS Alkermes plc compare | 4.6× |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 6.6× |
| AMLX Amylyx Pharmaceuticals, Inc. compare | 30.7× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)